Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Inclusion period was from 2015 to 2017 and study completion by December 2020.

Patients included were adults with a first-time diagnosis of GD treated with ATD.

Who Took Part

The abstract describes 4 patients taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

More than one site took part, so the patients came from several places.

What Was Measured

Topics PubMed links to this paper include Iodine Radioisotopes, Graves Disease, Antithyroid Agents, Vitamins, Dietary Supplements, Vitamin D and Recurrence.

Author keywords: Graves' disease, autoimmunity, clinical trial and thyroid diseases.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 4 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2023 (Thyroid : official journal of the American Thyroid Association), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.